SOUTH SAN FRANCISCO, Calif., Nov. 6 PortolaPharmaceuticals, a biopharmaceutical company developing innovative drugs thatprovide significant advances in cardiovascular and inflammatory diseases, andcancer, today announced that data relevant to betrixaban, the company's noveloral Factor Xa inhibitor and PRT060128, its novel ADP receptor antagonist,will be presented at the American Heart Association (AHA) Scientific Sessions2008. The conference will be held at the Ernest N. Morial Convention Centerin New Orleans, LA during November 8-12, 2008.
"We have important data being presented at AHA that demonstrate thepotential of our differentiated Phase II compounds that address major unmetneeds in preventing and treating thrombosis," said Charles Homcy, M.D.,president and chief executive officer of Portola. "In particular, data fromDr. Paul Gurbel show how our antiplatelet agent may be effective in a highpercentage of patients who do not respond adequately to clopidogrel, thecurrent standard of care. Additionally, data being presented will show thatour two Phase II agents, PRT060128 and betrixaban, our oral once-daily FXainhibitor, may work in combination to inhibit thrombosis without raisingbleeding risk. Together these data highlight some of the unique properties ofour lead antithrombotic compounds."
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals develops innovative therapeutics based on targetswith established proof of concept that are engineered to provide significantadvances over current treatments for cardiovascular and inflammatory diseasesand cancer.
Portola's two lead Phase II compounds, betrixaban, an oral Factor Xainhibitor and PRT060128, an ADP receptor antagonist, target the global multi-billion dollar antithrombotic market. Both product candidates have best-in-class features versus current and novel agents in development and address thehospital, specialty, and chronic care markets. The Company's earlier-stageprograms are leveraging its chemistry and kinase expertise to develop specificSyk and JAK inhibitors to treat cancer and inflammatory diseases with broaderactivity. The company also has a novel anticoagulant antidote program withthe potential to help manage the more than 20 million patients expected to betreated with anticoagulants worldwide in the next decade. For additionalinformation, visit http://www.portola.com.Following are the details on each poster presentation. Monday, November 10 Poster Title: "Combination of Direct Acting FXa Inhibitor and P2Y12 Antagonist at Non-Effective Doses Provides Significant Inhibition of Arterial Thrombosis" Patrick Andre et al Time: 9:00 a.m. - 5:00 p.m. Hall A-B1, Poster Board B129 Wednesday, November 12 Poster Title: "Oral Dosing of PRT060128, a Novel Direct-acting, Reversible P2Y12 Antagonist Overcomes High Platelet Reactivity in Patients Non-responsive to Clopidogrel Therapy" Paul A. Gurbel et al Time: 9:00 a.m. - 5:00 p.m. Hall A-B1, Poster Board C6
SOURCE Portola Pharmaceuticals, Inc.